Trial Profile
Extended Duration Artemether-lumefantrine Treatment for Malaria in Children
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Artemether/lumefantrine (Primary)
- Indications Falciparum malaria
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms EXALT
- 20 Sep 2022 Primary endpoint has not been met (Recurrent malaria following treatment by day 42 (recrudescence or new infection)) , according to Results published in the Clinical Infectious Diseases
- 20 Sep 2022 Results published in the Clinical Infectious Diseases
- 28 May 2021 Status changed from active, no longer recruiting to completed.